BCC Research has published a Pulse research titled “AI Impact on Neuroprotective Agents” that maps how artificial intelligence is changing the discovery, development and delivery of neuroprotective therapies.
The research forecasts the North American neuroprotective agents market to grow at about a 4.5% CAGR through 2030 and highlights hundreds of millions of dollars flowing into AI-driven neuroscience startups. It identifies recent venture raises, including Nilo Therapeutics ($101 million), Verge Genomics ($98 million), Chai Discovery ($70 million), NRG Therapeutics ($65.6 million), BEXORG ($42.5 million) and Illimis Therapeutics ($42 million).
The research documents intensifying pharma-tech collaborations, such as Eli Lilly’s partnership with NVIDIA to build an AI supercomputer, a $200 million joint venture between MeiraGTx and Hologen, and Biogen’s work with TheraPanacea. It describes AI use across the value chain from target identification and generative molecule design to predictive trial optimization, digital biomarker development and precision dosing, and flags trends including multi-target strategies, digital twins for patient modeling and blood-brain barrier penetration prediction tools.
The research frames these developments as creating new investor opportunities. The company claims it provides objective market measurement and analysis to inform strategic decision-making.
